Synairgen PLC | Balance Sheet

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,292.00
9,599.00
7,714.00
4,765.00
6,845.00
5,334
Total Accounts Receivable
196.00
73.00
320.00
609.00
704.00
1,011
Inventories
199.00
56.00
56.00
55.00
56.00
56
Other Current Assets
37.00
84.00
95.00
41.00
-
-
Total Current Assets
1,724.00
9,812.00
8,185.00
5,470.00
7,605.00
6,401
Net Property, Plant & Equipment
15.00
17.00
17.00
13.00
12.00
374
Intangible Assets
297.00
102.00
81.00
62.00
45.00
29
Total Assets
2,036.00
9,931.00
8,283.00
5,545.00
7,662.00
6,804
Accounts Payable
20.00
78.00
281.00
356.00
282.00
Other Current Liabilities
437.00
417.00
655.00
504.00
821.00
Total Current Liabilities
457.00
495.00
936.00
860.00
1,103.00
Total Liabilities
457.00
495.00
936.00
860.00
1,103.00
Common Equity (Total)
1,579.00
9,436.00
7,347.00
4,685.00
6,559.00
Total Shareholders' Equity
1,579.00
9,436.00
7,347.00
4,685.00
6,559.00
Total Equity
1,579.00
9,436.00
7,347.00
4,685.00
6,559.00
Liabilities & Shareholders' Equity
2,036.00
9,931.00
8,283.00
5,545.00
7,662.00

About Synairgen

View Profile
Address
Mailpoint 810, Level F, South Block
Southampton London & South East SO16 6YD
United Kingdom
Employees -
Website http://synairgen.com
Updated 07/08/2019
Synairgen Plc is a holding company, which engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease, and severe viral infections. The company was founded by Donna E.